Research progress on recombinant human endostatin combined with radiotherapy and / or chemotherapy in the treatment of cervical cancer
10.3760/cma.j.cn113030-20211117-00469
- VernacularTitle:重组人血管内皮抑制素联合放化疗治疗宫颈癌研究进展
- Author:
Xin LI
1
;
Lijun HU
;
Jingping YU
Author Information
1. 蚌埠医学院研究生院，蚌埠 233000
- Keywords:
Uterine cervical neoplasms;
Radiotherapy;
Targeted therapy;
Recombinant human endostatin;
Chemotherapy
- From:
Chinese Journal of Radiation Oncology
2023;32(1):75-80
- CountryChina
- Language:Chinese
-
Abstract:
Cervical cancer is one of the most common malignant tumors in women worldwide. Locally advanced cervical cancer is mainly treated with radiotherapy and chemotherapy, but there are problems such as high recurrence rate and low survival rate. Bevacizumab, an angiogenic inhibitor that acts on vascular endothelial growth factor (VEGF), has been recommended by the National Comprehensive Cancer Network (NCCN) guidelines for the first-line treatment of recurrent / metastatic advanced cervical cancer in 2013. In recent years, the development of new targeted drugs for angiogenesis inhibitors, such as endostatin, has further optimized the new targeted therapy strategy for patients with locally advanced and advanced cervical cancer. Recombinant human endostatin (endostar) is a novel anti-angiogenesis drug independently developed by Chinese scientists. Although it has been applied in the treatment of cervical cancer, it needs to be further confirmed by high level evidence based medical evidence whether it can become a new option for targeted treatment of cervical cancer. In this article, clinical research progress on the treatment of cervical cancer by endostar combined with radiotherapy and / or chemotherapy was reviewed, aiming to provide reference for the optimization of cervical cancer treatment strategy.
